IP Library Granted Patent US 10,577,427
Granted Patent B2
US 10,577,427 · App. 16/091,077 · Granted Mar 3, 2020

Integral membrane protein display on poxvirus extracellular enveloped virions

Inventors: Ernest S. Smith (W. Henrietta, NY); Mark Paris (Mendon, NY); Maria G. M. Scrivens (Rochester, NY); Renee A. Kirk (Bloomfield, NY); Angelica A. Cornelison (Pittsford, NY)
Assignee: Vaccinex, Inc.
C07K16/32C07K14/005C07K14/70503C07K14/70596C07K14/71C07K14/7158C07K14/723C07K16/2866C07K16/2869C07K16/2896C12N15/86C07K2319/01C07K2319/02C07K2319/21C12N2710/24121C12N2710/24122C12N2710/24143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,577,427
App. No.
16/091,077
Granted
Mar 3, 2020
Kind
B2
Abstract

This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.

Claims (27)

1. An IMP-EEV fusion protein, which comprises

(a) an integral membrane protein (IMP) or fragment thereof, which comprises at least one extra-membrane region, at least one transmembrane domain, and at least one intra-membrane region; and

(b) a vaccinia virus extracellular enveloped virion (EEV) protein or functional fragment thereof.

2. The IMP-EEV fusion protein of claim 1 , comprising:

(a) amino acids 20 to 892 of SEQ ID NO: 2;

(b) SEQ ID NO: 3;

(c) SEQ ID NO: 4;

(d) amino acids 20 to 370 of SEQ ID NO: 6;

(e) amino acids 20 to 855 of SEQ ID NO: 7;

(f) amino acids 20 to 935 of SEQ ID NO: 8;

(g) amino acids 20 to 243 of SEQ ID NO: 10; or

(h) amino acids 20 to 281 of SEQ ID NO: 11.

3. A recombinant poxvirus EEV, comprising the IMP-EEV fusion protein of claim 2 .

4. A recombinant poxvirus EEV, comprising the IMP-EEV fusion protein of claim 1 , wherein the IMP or fragment thereof is heterologous to the EEV protein fused thereto, wherein the IMP-EEV fusion protein is situated in the outer envelope membrane and the IMP or fragment thereof is displayed on the surface of the outer membrane in its native conformation.

5. The recombinant poxvirus EEV of claim 4 , wherein the poxvirus EEV is a vaccinia virus EEV.

6. A method of selecting antibodies that bind to a multi-pass membrane protein, which comprises:

(a) attaching a vaccinia virus that expresses the IMP-EEV fusion protein of claim 1 , wherein the IMP or fragment thereof is expressed on the surface of its outer membrane protein, to a solid support;

(b) providing an antibody display library, wherein the library comprises display packages displaying a plurality of antigen binding domains;

(c) contacting the display library with the vaccinia virus such that display packages displaying antigen binding domains that specifically binds to the IMP can bind thereto;

(d) removing unbound display packages; and

(e) recovering display packages having antigen binding domains bound to the IMP or fragment thereof.

7. The method of claim 6 , wherein the vaccinia virus is attached to the solid surface via reaction with tosyl groups on the solid surface.

8. The method of claim 7 , wherein the solid surface is tosyl-activated magnetic beads.

9. The method of claim 6 , wherein the vaccinia virus is biotinylated and attached to a streptavidin coated solid surface.

10. The method of claim 9 , wherein the solid surface is streptavidin-coated magnetic beads.

11. The IMP-EEV fusion protein of claim 1 , wherein the IMP or fragment thereof is fused at its C-terminus to the EEV protein.

12. The IMP-EEV fusion protein of claim 1 , wherein the IMP or fragment thereof is fused at its N-terminus to the EEV protein.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 9, 2023
From: VACCINEX, INC.
To: 3I, L.P.
Reel/Frame 062308/0405 →
SECURITY INTEREST Recorded Aug 10, 2020
From: VACCINEX, INC.
To: 3I, L.P.
Reel/Frame 053440/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2018
From: SMITH, ERNEST S.; PARIS, MARK; SCRIVENS, MARIA G.M.; KIRK, RENEE; CORNELISON, ANGELICA
To: VACCINEX, INC.
Reel/Frame 047060/0128 →